qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen
The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary more ..
BioActive Compounds: 736
The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is governed by the recruitment of coactivators. Our hypothesis is that small molecules, with the ability to inhibit the interaction between VDR and certain coactivators, are able to selectively modulate VDR-mediated transcription. Our long term objective is the application these VDR-coactivator inhibitors to study the role of VDR-coactivator binding for specific VDR regulated genes. Ultimately, these molecules can be developed into new treatments for hypercalcemic hyperparathyroidism. No small molecule or non-peptide inhibitors are known for the VDR-coactivator interaction.
In a collaboration between the University of Wisconsin, Milwaukee and the NIH Chemical Genomics Center (NCGC) a HTS-compatible enzymatic assay was developed. The assay uses fluorescence polarization as its read-out to measure the inhibition between VDR and coregulator peptide SRC2-3 exerted by small molecules. This assay was used to screen the NIH Molecular Libraries Small Molecule Repository (MLSMR).
NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Centers Network [MLPCN]
MLPCN Grant: DA031090
Assay Submitter (PI): Alexander Arnold, University of Wilwaukee
Four microliter of either 800nM VDR, 5uM LG19078, and 15nM SRC2-3 Alexa 647 (all final concentrations) in columns 1, 2, and 5 to 48 or 15nM SRC2-3 Alexa 647 in columns 3 and 4 are dispensed into black medium-binding solid bottom Greiner plates. Both solutions are kept at 4 deg C and protected from light and dispensed using a Kalypsys dispenser. Then 23nl of compounds and controls are added with Kalypsys pintool. The control is 26.5mM CBT358 (final concentration of 151uM) and the compounds' final range in concentration is 457nM - 114uM. Plate is centrifuged at 1000 RPM for 15 seconds to remove any residual bubbles. The plate is then incubate at ambient room temperature for 2 hours. It is then read on the Envision for a fluorescent polarization read-out (Ex 620 nm/Em 688 nM)
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Categorized Comment - additional comments and annotations
* Activity Concentration. ** Test Concentration.
Data Table (Concise)